Can Animal-Inspired Longevity Biotechs Clear The Return Hurdle?

Before going deeper into a longevity biotech that passes our first gate: potential relevance to extending healthy life, we need to ask another question: at the price we could invest, is there a reasonable path to getting back 10 times our money or more, after dilution?

This is a very important skill to develop. A company can do valuable work, develop an effective treatment, and still be a disappointing investment if we pay too much for it.

Biotech has many hurdles between an interesting discovery and a treatment that reaches patients. Experiments may fail. Trials take years. More money often has to be raised, reducing an existing investor’s share of the eventual outcome. Some investments can be lost entirely. Looking for substantial upside in the investments that succeed can help offset those potential losses, although it does not guarantee a profitable portfolio.

That is why our financial screen starts with a credible possibility of 10×+ to the investor after dilution. We are not predicting that return. We are asking whether there is enough potential to justify spending more time on the company.

Lilly completed its acquisition of Verve Therapeutics in July 2025. The deal offered approximately $1 billion upfront, with a conditional payment that could bring the total to about $1.3 billion. That sounds like a successful company outcome. It tells us much less about the outcome for an individual investor. Deal terms; completion.

The relationship developed before the purchase: Lilly began collaborating with Verve and bought shares in 2023, then acquired it in 2025. That was a concrete signal of growing interest, not a guarantee of a good return at any entry price. It also came after the 2021 offering, so we cannot use it as evidence available to an investor then. Relationship history.

Someone allocated shares at Verve’s $19 first public share offering price in 2021 received $10.50 per share in cash at the acquisition: about 0.55× the original investment, a 45% loss. Even the maximum additional $3 per share, if earned, would bring that to only about 0.71×. share-offering document.

For comparison, a hypothetical investor who paid $5 per share would receive 2.1× from the same $10.50 cash payment. That $5 is an illustration, not a claim about a particular financing round. The same acquisition can produce a loss for one investor and a gain for another.

There is another useful lesson. At its public share offering price, Verve had a basic equity value of roughly $916 million under the prospectus’s full underwriter-option assumption. Novartis had agreed to buy The Medicines Company for $9.7 billion. Its drug and Verve’s lead both aimed to lower blood cholesterol through the same liver protein involved in controlling blood cholesterol, but used repeat dosing versus a lasting gene edit. That makes it a relevant treatment-market comparison, with different safety and durability questions. Divide one by the other and a possible 10× story appears. But the comparison needs judgment. When its deal was announced in 2019, The Medicines Company’s inclisiran had Phase 3 data from more than 3,600 trial participants. Novartis announcement.

Verve was preclinical at its June 2021 public share offering: its lead treatment had not been tested in people. It planned to seek clearance for human trials in 2022, after completing the necessary safety and manufacturing work. It then faced Phase 1 safety and dose testing (generally several months, potentially longer for gene editing), Phase 2 early effectiveness testing (several months to two years), and Phase 3 confirmation in larger populations (one to four years) to reach evidence comparable to inclisiran’s. Review for permission to sell the medicine could add roughly six to ten months or longer. These are general timelines, not Verve’s promised schedule.

The investment implication: Verve still faced years of work, spending and possible fundraising before reaching comparable evidence. It could be acquired earlier, but we should not assume an earlier buyer would pay the same $9.7 billion.

Verve’s proposed lasting effect from gene editing could have meaningful value. The question is how much value, for which patients, with what safety evidence, and how much of that eventual value an investor could retain. The acquisition headline alone cannot answer that.

We will never have perfectly matched comparables or precise forecasts for an early biotech. We can still use a consistent process to make a useful ballpark estimate and notice what we might otherwise miss.

The goal is to look at a company reasonably quickly and say: “This might have a credible path to 10×+ after dilution. It deserves more investigation.” Or: “I don’t see enough potential at this price. Let’s watch for a change, or pass for now.”

Build the skill to spot which longevity biotechs may offer 10×+ potential after dilution - without spending hours on every company.

In the members’ lesson, make your own assessment through short, guided exercises, then compare it with mine. See which assumptions matter and what you overlooked. Each comparison sharpens your judgment for the next company.

Join now to build a repeatable process for deciding what deserves deeper research, what belongs on your watchlist and what to pass on.